DMF and, more so, its active metabolite, monomethyl fumarate, are known agonists of the hydroxycarboxylic acid receptor 2 (HCA 2), a G protein-coupled membrane receptor.
DMF decreased the number of infiltrating neutrophils in a HCA 2 -dependent manner, likely by interfering with neutrophil adhesion to endothelial cells and chemotaxis.